Noticeably, primary bone marrow cells from five CML-BC patients treated with Icaritin exhibited significant apoptosis in a dose-dependent manner, as revealed with the annexin V assays (Fig. 2D). The gene discussed is ANXA5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.